17/11/2004

Holding(s) in Company

25/10/2004

Completion of Acquisition of Guildford Clinical Pharmacology Unit Limited

19/10/2004

Regen Therapeutics Plc to acquire Guildford Clinical Pharmacology Unit Limited

15/09/2004

Interim Results for the Six Months to 30 June 2004

15/09/2004

Interim Results for the Six Months to 30 June 2004

22/07/2004

Pre-treatment of Cells with Colostrinin™ Prevents Aggregation and Toxicity of Beta Amyloid

10/07/2004

Substantial Shareholding

16/06/2004

In-vivo Study in Chicks shows ReGen’s Colostrinin™ enhances memory

09/06/2004

Reduction of Memory Impairment

20/05/2004

US Laboratory Studies show the potential of ReGen’s Colostrinin™ to impact pathologies involved in Alzheimer’s disease

20/04/2004

AGM Statement

20/04/2004

Results of Annual General Meeting

05/04/2004

Research Update

05/04/2004

New York visit by ReGen Chairman

19/03/2004

Notice of AGM

19/03/2004

Research Update

17/03/2004

Colostrinin (1) (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer’s disease

17/03/2004

Colostrinin™ Clinical Study is published in Journal of Alzheimer’s Disease

13/02/2004

Notification of Change in Interests of Directors

12/02/2004

ReGen Therapeutics Plc Placing raises £500,000

12/02/2004

Preliminary results to 31 December 2003

26/01/2004

Disclosure of Notifiable Interest – Disposal of Shares

23/12/2003

ReGen Therapeutics Plc Placing raises £93,400

17/12/2003

Declaration of Shareholding

12/12/2003

Substantial Shareholding

10/12/2003

Research & Development Update

10/12/2003

Placing raises £655,000

13/11/2003

Notice of EGM

12/11/2003

Results of EGM

08/10/2003

Colostrinin™ Clinical Study to be published in Journal of Alzheimer’s Disease

08/10/2003

Substantial shareholding

24/09/2003

Interim Results for the Six Months to 30 June 2003

23/07/2003

Holding(s) in Company 2003

16/07/2003

Substantial Shareholding 2003

15/07/2003

ReGen Therapeutics placing raises £954,000

03/07/2003

Notification of shareholding 2 – 2003

01/07/2003

Notification of shareholding 1 – 2003

19/06/2003

Disposal of shares 2003

10/06/2003

Results of Annual General Meeting

31/05/2003

The Wall Street Transcript – Interview with Percy Lomax (Executive Chairman)

27/05/2003

Substantial Holdings 2 – 2003

17/04/2003

Interim Funding 2 – 2003

15/04/2003

Substantial Holdings 2003

10/04/2003

Interim Funding 2003

10/03/2003

Capital Reorganisation

05/03/2003

Preliminary results to December 2002

03/03/2003

Results of Extraordinary General Meeting

04/02/2003

Change of adviser 2003

22/01/2003

ReGen Therapeutics enters into Condiditonal Placing Commitment with Jubilee Investment Trust Plc

09/01/2003

ReGen Therapeutics announces grant of U.S patent on use of Colostrinin™ as an oxidative stress regulator

14/11/2002

Notice of EGM 2002

14/11/2002

Resignation of board member 2002

13/11/2002

Publication of independent long-term study on Colostrinin™ shows positive results

24/10/2002

ReGen presents potential mode of action data for Colostrinin™ at International Conference on Alzheimer’s Disease

17/10/2002

Patent Granted 2002

12/10/2002

Directors Appointed at ReGen Therapeutics Plc

12/10/2002

Results of EGM & Analysts’ Presentation

26/09/2002

Interim Results for the 6 months to 30 June 2002

24/09/2002

Regen secures potential funding facility

17/09/2002

Update on potential funding

02/09/2002

Board Restructuring 2002

11/07/2002

Substantial Shareholding 2 – 2002

08/07/2002

Announcement 08/07/2002

19/06/2002

Substantial Shareholding 1 – 2002

10/06/2002

ReGen Therapeutics successfully completes Interim funding round

08/05/2002

Preliminary Results for the Year Ended 31 December 2001

22/03/2002

Colostrinin™ continues trends towards efficacy in latest Interim findings from Clinical trial

04/03/2002

Share Issue 2002

29/01/2002

Result of EGM 2002

16/01/2002

Board Changes 2002

18/12/2001

Share Issue

06/12/2001

Further fundraising

19/11/2001

ReGen strengthen it’s Colostrinin™ IP rights

06/11/2001

Directors shareholdings

05/11/2001

Placing of ordinary shares

30/10/2001

ReGen to acquire full ownership of its Colostrinin™ IP rights

26/10/2001

Trial recruitment complete

17/10/2001

Update on placing of ordinary shares

11/10/2001

Placing of Ordinary Shares

28/09/2001

Interim Results announcement for the six months ended 30 June 2001

16/07/2001

Shares in Issue: 52.54m 5p Ordinary shares

11/04/2001

Colostrinin™ Clinical Trial – Interim Data Assessment

07/04/2001

Board Change

19/02/2001

Michael Harvey appointed Chief Executive Officer of ReGen Therapeutics Plc

16/10/2000

ReGen Therapeutics strength organisation ahead of trial results and appoints Ernst and Young as nominated Adviser

30/07/2000

Interim Results for the six months to 30 June 2000

21/07/2000

Clinical Trials, Scientific and Manufacturing update

20/07/2000

AGM Statement

16/07/2000

Key Financials

16/07/2000

ReGen Therapeutics is developing a therapy for Alzheimer’s disease based on Colostrinin

23/03/2000

ReGen Therapeitics Plc public offer oversubscribed ten times. AIM Dealings start at 8AM, 24 th March

15/03/2000

ReGen Therapeutics Plc plan AIM debut on 24 March 2000

24/02/2000

Regen Therapeutics Plc complete £4.25 million placing, Public offer opens to raise £750,000 prior to move to alternative investment market (AIM)

03/02/2000

Managing Director, Joins ReGen Therapeutics from Medeva ahead of AIM Flotation

11/01/2000

Board Appointment for ReGen Therapeutics Plc